WO1999016466A3 - Vaccine compositions and methods of enhancing vaccine efficacy - Google Patents

Vaccine compositions and methods of enhancing vaccine efficacy Download PDF

Info

Publication number
WO1999016466A3
WO1999016466A3 PCT/US1998/020321 US9820321W WO9916466A3 WO 1999016466 A3 WO1999016466 A3 WO 1999016466A3 US 9820321 W US9820321 W US 9820321W WO 9916466 A3 WO9916466 A3 WO 9916466A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
methods
enhancing
efficacy
compositions
Prior art date
Application number
PCT/US1998/020321
Other languages
French (fr)
Other versions
WO1999016466A2 (en
Inventor
Norman L Letvin
Dan H Barouch
Original Assignee
Beth Israel Hospital
Norman L Letvin
Dan H Barouch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Norman L Letvin, Dan H Barouch filed Critical Beth Israel Hospital
Priority to AU95883/98A priority Critical patent/AU9588398A/en
Publication of WO1999016466A2 publication Critical patent/WO1999016466A2/en
Publication of WO1999016466A3 publication Critical patent/WO1999016466A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides methods, vaccine compositions and plasmid constructs which enhance the immune response of a vaccine.
PCT/US1998/020321 1997-09-29 1998-09-29 Vaccine compositions and methods of enhancing vaccine efficacy WO1999016466A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU95883/98A AU9588398A (en) 1997-09-29 1998-09-29 Vaccine compositions and methods of enhancing vaccine efficacy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6033897P 1997-09-29 1997-09-29
US60/060,338 1997-09-29
US99018097A 1997-12-12 1997-12-12
US08/990,180 1997-12-12

Publications (2)

Publication Number Publication Date
WO1999016466A2 WO1999016466A2 (en) 1999-04-08
WO1999016466A3 true WO1999016466A3 (en) 1999-06-03

Family

ID=26739829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/020321 WO1999016466A2 (en) 1997-09-29 1998-09-29 Vaccine compositions and methods of enhancing vaccine efficacy

Country Status (2)

Country Link
AU (1) AU9588398A (en)
WO (1) WO1999016466A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
WO2000015249A1 (en) * 1998-09-15 2000-03-23 Genetics Institute, Inc. Treatment of kaposi's sarcoma with il-12
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
BRPI0404983A (en) * 2004-09-03 2006-05-02 Nanocore Biotecnologia Ltda immunogenic compositions
WO2007061759A1 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delayed expression vectors
WO2013040040A1 (en) * 2011-09-12 2013-03-21 New York University School Of Medicine Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. WEINBERG ET AL.: "Recombinant interleukin 2 as an adjuvant for vaccine-induced protection.", THE JOURNAL OF IMMUNOLOGY, vol. 140, no. 1, 1 January 1988 (1988-01-01), Baltimore, MD, USA, pages 294 - 299, XP002097490 *
C. LEKUTIS ET AL.: "HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.", THE JOURNAL OF IMMUNOLOGY, vol. 158, no. 9, 1 May 1997 (1997-05-01), Baltimore, MD, USA, pages 4471 - 4477, XP002097489 *
D. BAROUCH ET AL.: "Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration.", THE JOURNAL OF IMMUNOLOGY, vol. 161, no. 4, 15 August 1998 (1998-08-15), Baltimore, MD, USA, pages 1875 - 1882, XP002097493 *
J. VIEWEG ET AL.: "Preclinical studies toward gene therapy of prostate cancer", JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT, vol. 21A, 1995, New York, NY, USA, pages 360, XP002097488 *
N. LETVIN ET AL.: "Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 94, no. 17, 19 August 1997 (1997-08-19), Washington, DC, USA, pages 9378 - 9383, XP002097492 *
S. PRAYAGA ET AL.: "Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization.", VACCINE, vol. 15, no. 12/13, August 1997 (1997-08-01), Guildford, GB, pages 1349 - 1352, XP002097491 *

Also Published As

Publication number Publication date
WO1999016466A2 (en) 1999-04-08
AU9588398A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
ZA9811848B (en) Vaccine.
WO2004016805A3 (en) Immunostimulatory nucleic acids
HK1016472A1 (en) Activated protein c formulations.
WO2001010380A3 (en) Benzanilides as potassium channel openers
HK1043731A1 (en) Vaccine against antigens from bacteriae
WO2000002522A3 (en) Anthrax vaccine
AU6065998A (en) Influenza vaccine
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2004060319A3 (en) Immunostimulatory combinations
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
WO2003002142A8 (en) Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
ZA200004956B (en) Vaccine composition.
AU3760100A (en) Immunostimulatory nucleic acids and antigens
MXPA03007915A (en) Vaccine.
ZA973642B (en) DNA vaccine formulations.
AU2002307971A1 (en) Vaccine against the nile fever virus
WO1999016466A3 (en) Vaccine compositions and methods of enhancing vaccine efficacy
AU2001227960A1 (en) Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
WO2002076384A3 (en) Therapeutic compositions that alter the immune response
AU2001269578A1 (en) Armature for heat shrinkable sleeve and heat shrinkable sleeve comprising it
WO2000059831A3 (en) Cleavable, water-soluble surfactants
ZA9710205B (en) Bacterial antigens and vaccine compositions II.
AU7471098A (en) Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents
WO2003000624A3 (en) Igniting agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA